TABLE 5

Treatment outcomes of the whole cohort and comparison between patients receiving standard (≤190 days) or prolonged (>190 days) bedaquiline treatment

Whole cohortStandard bedaquiline treatmentProlonged bedaquiline treatmentp-value#
Subjects451233
Favourable outcomes36 (80.0)9 (75.0)27 (81.8)0.682
 Cured34 (75.6)7 (58.3)27 (81.8)0.131
 Treatment completed2 (4.4)2 (16.7)00.067
Unfavourable outcomes9 (20.0)3 (25.0)6 (18.2)1.000
 Lost to follow-up5 (11.1)2 (16.7)3 (9.1)0.598
 Died3 (6.7)1 (8.3)2 (6.1)1.000
 Treatment failed1 (2.2)01 (3.0)1.000
Follow-up at 12 months
 No recurrence23 (63.9)4 (44.4)19 (70.4)0.235
 Lost to follow-up9 (25.0)5 (55.6)4 (14.8)0.026
 Died1 (2.8)01 (3.7)1.000
 Censored3 (8.3)03 (11.1)0.558
Follow-up at 24 months
 No recurrence4 (17.4)1 (25.0)3 (15.8)1.000
 Lost to follow-up2 (8.7)02 (10.5)1.000
 Died1 (3.7)1 (25.0)00.174
 Censored16 (69.6)2 (50.0)14 (73.7)0.557
Time to sputum smear conversion90 (36–173)71 (22–90)110 (47–195)0.002
Time to sputum culture conversion89 (45–107)71 (53–88)91 (43–114)0.021
  • Data are presented as n, n (%) or median (interquartile range), unless otherwise stated. #: comparison between patients with standard and prolonged bedaquiline treatment, calculated with Wilcoxon's test for continuous variables and Fisher's exact test for categorical variables; : patients eligible for follow-up are those with favourable outcomes at the previous time point (12 months: n=36 whole cohort, n=9 standard treatment and n=27 prolonged treatment; 24 months: n=23 whole cohort, n=4 standard treatment and n=19 prolonged treatment).